Pharmacologic Substance
FDA Awaits Final Decision on Madrigal’s Resmetirom for NASH Treatment with Priority Review and NDA Acceptance Set for March 14, 2024
Nonalcoholic Steatohepatitis, resmetirom, United States Food and Drug Administration, New Drug Application, Priority Review, Fibrosis, Liver, Liver, Madrigal’s, March 14, 2024
Kyowa Kirin Partners with BridgeBio for Potential Achondroplasia Drug, Pays $100M in Pivotal Collaboration
Achondroplasia, infigratinib, BridgeBio, Kyowa, Kirin, Collaboration
Jazz Pharmaceuticals Expands Oncology Pipeline with Redx’s KRAS Inhibitor Program
Kirsten murine sarcoma virus, Jazz, Redx, Inhibitor
Amgen’s obesity drug takes the weight off and may keep it off, too, early data suggest
Obesity, MariTide, Weight Loss, Source, Amgen’s, weight off
With subpar sales for Leqembi, Eisai delays Alzheimers patient goal deadline
Leqembi, Alzheimer’s Disease, Eisai, subpar sales
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined